RS60541B1 - Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa - Google Patents

Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa

Info

Publication number: RS60541B1
Authority: RS; Serbia
Prior art keywords: acitivation; compositions; dependent complement; inhibiting masp; masp
Prior art date: 2011-05-04

Application number

RS20200685A

Other languages

English (en)

Inventor

Thomas Dudler

Wayne R Gombotz

James Brian Parent

Clark E Tedford

Anita Kavlie

Urs Beat Hagemann

Herald Reiersen

Sergej Kiprijanov

Original Assignee

Omeros Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-04

Filing date

2012-05-04

Publication date

2020-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47090380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS60541(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-05-04 Application filed by Omeros Corp filed Critical Omeros Corp

2020-08-31 Publication of RS60541B1 publication Critical patent/RS60541B1/sr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

RS20200685A 2011-05-04 2012-05-04 Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa RS60541B1 (sr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161482567P	2011-05-04	2011-05-04
PCT/US2012/036509 WO2012151481A1 (en)	2011-05-04	2012-05-04	Compositions for inhibiting masp-2 dependent complement acitivation
EP12779347.9A EP2704743B1 (en)	2011-05-04	2012-05-04	Compositions for inhibiting masp-2 dependent complement acitivation

Publications (1)

Publication Number	Publication Date
RS60541B1 true RS60541B1 (sr)	2020-08-31

Family

ID=47090380

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20200685A RS60541B1 (sr)	2011-05-04	2012-05-04	Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa

Country Status (26)

Country	Link
US (6)	US9011860B2 (sr)
EP (2)	EP2704743B1 (sr)
JP (6)	JP5891298B2 (sr)
KR (3)	KR101641057B1 (sr)
CN (2)	CN107011443B (sr)
AU (1)	AU2012250627B2 (sr)
BR (1)	BR112013028429B1 (sr)
CA (3)	CA3131223C (sr)
CL (1)	CL2013003140A1 (sr)
CY (1)	CY1123212T1 (sr)
DK (1)	DK2704743T3 (sr)
ES (1)	ES2795667T3 (sr)
HR (1)	HRP20200887T1 (sr)
HU (1)	HUE049154T2 (sr)
IL (4)	IL229208B (sr)
LT (1)	LT2704743T (sr)
ME (1)	ME03755B (sr)
MX (3)	MX347691B (sr)
PL (1)	PL2704743T3 (sr)
PT (1)	PT2704743T (sr)
RS (1)	RS60541B1 (sr)
RU (3)	RU2636038C2 (sr)
SI (1)	SI2704743T1 (sr)
SM (1)	SMT202000294T1 (sr)
WO (1)	WO2012151481A1 (sr)
ZA (1)	ZA201308943B (sr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
BRPI0911431B8 (pt)	2008-04-11	2021-05-25	Chugai Pharmaceutical Co Ltd	composição farmacêutica compreendendo um antígeno e método para aumentar o número de antígenos que podem ser ligados por um anticorpo
JP6030452B2 (ja)	2010-11-30	2016-11-24	中外製薬株式会社	複数分子の抗原に繰り返し結合する抗原結合分子
US9644035B2 (en)	2011-04-08	2017-05-09	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
NZ617298A (en)	2011-04-08	2015-08-28	Univ Leicester	Methods for treating conditions associated with masp-2 dependent complement activation
RS60541B1 (sr) *	2011-05-04	2020-08-31	Omeros Corp	Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
EP3597747B1 (en)	2012-08-24	2023-03-15	Chugai Seiyaku Kabushiki Kaisha	Mouse fcgammarii-specific fc antibody
EP3722320A3 (en)	2012-10-25	2020-12-30	Bioverativ USA Inc.	Anti-complement c1s antibodies and uses thereof
WO2014071206A1 (en)	2012-11-02	2014-05-08	True North Therapeutics, Inc.	Anti-complement c1s antibodies and uses thereof
US20140363433A1 (en)	2013-03-15	2014-12-11	Omeros Corporation	Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
CA2906096C (en) *	2013-03-15	2022-03-15	Omeros Corporation	Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
CN105246914B (zh)	2013-04-02	2021-08-27	中外制药株式会社	Fc区变体
EP3750919A1 (en) *	2013-10-17	2020-12-16	Omeros Corporation	Methods for treating conditions associated with masp-2 dependent complement activation
KR102650420B1 (ko)	2014-12-19	2024-03-21	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
TW202248212A (zh) *	2015-02-05	2022-12-16	日商中外製藥股份有限公司	包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
FI3280440T3 (fi)	2015-04-06	2023-03-09	Bioverativ Usa Inc	Humanisoituja anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
CN106699888B (zh) *	2015-07-28	2020-11-06	上海昀怡健康科技发展有限公司	一种pd-1抗体及其制备方法和应用
IL295200B1 (en)	2015-11-09	2024-12-01	Omeros Corp	COMPOSITIONS COMPRISING MASP-2 INHIBITORY ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF FOR USE IN TREATING PLASMA THERAPY-RESISTANT aHUS
JP7141336B2 (ja)	2015-12-25	2022-09-22	中外製薬株式会社	抗ミオスタチン抗体および使用方法
CA3185172A1 (en)	2016-01-05	2017-07-13	Omeros Corporation	Methods for inhibiting fibrosis in a subject in need thereof
KR20180128941A (ko) *	2016-03-31	2018-12-04	오메로스 코포레이션	혈관 형성의 억제를 필요로 하는 대상체에서 혈관 형성을 억제하는 방법
JOP20170154B1 (ar) *	2016-08-01	2023-03-28	Omeros Corp	تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
CN109689099B (zh)	2016-08-05	2023-02-28	中外制药株式会社	用于预防或治疗il-8相关疾病的组合物
JOP20170170B1 (ar) *	2016-08-31	2022-09-15	Omeros Corp	صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JOP20190068A1 (ar) *	2016-10-13	2019-04-01	Omeros Corp	طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
TWI818919B (zh)	2017-08-15	2023-10-21	美商歐米諾斯公司	用於治療和／或預防與造血幹細胞移植有關的移植物抗宿主病和／或瀰漫性肺泡出血和／或靜脈閉塞性病的方法
CN111278863A (zh) *	2017-08-25	2020-06-12	奥默罗斯公司	高浓缩低粘度masp-2抑制性抗体制剂、试剂盒和治疗患有非典型溶血综合征的受试者的方法
WO2019177543A1 (en)	2018-03-15	2019-09-19	Chugai Seiyaku Kabushiki Kaisha	Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
SG11202010925UA (en)	2018-05-29	2020-12-30	Omeros Corp	Masp-2 inhibitors and methods of use
US11584714B2 (en)	2018-05-29	2023-02-21	Omeros Corporation	MASP-2 inhibitors and methods of use
FI3893924T3 (fi) *	2018-12-13	2024-10-04	argenx BV	Ihmisen komplementtitekijän C2B vasta-aineita sekä niiden käyttötapoja
EP4069358A1 (en)	2019-12-04	2022-10-12	Omeros Corporation	Masp-2 inhibitors and methods of use
WO2021113698A1 (en)	2019-12-04	2021-06-10	Omeros Corporation	Masp-2 inhibitors and methods of use
AU2020396565B2 (en)	2019-12-04	2025-01-09	Omeros Corporation	MASP-2 inhibitors and methods of use
EP4069678A1 (en)	2019-12-04	2022-10-12	Omeros Corporation	Masp-2 inhibitors and methods of use
TWI834025B (zh)	2020-03-06	2024-03-01	美商奥默羅斯公司	用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法
CN114634575A (zh) *	2020-12-16	2022-06-17	康诺亚生物医药科技（成都）有限公司	一种补体抑制剂的开发和应用
AU2022216290A1 (en) *	2021-02-05	2023-09-14	Omeros Corporation	Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
CN115215937B (zh) *	2021-04-15	2023-05-26	上海麦济生物技术有限公司	抗人masp-2抗体及其制备方法和应用
AU2022263683A1 (en)	2021-04-25	2023-11-23	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Anti-masp2 antibody, antigen-binding fragment thereof and medical use thereof
AU2022405100A1 (en) *	2021-12-10	2024-07-25	Omeros Corporation	Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
CN116615544A (zh) *	2021-12-10	2023-08-18	舒泰神（北京）生物制药股份有限公司	特异性识别masp2的抗体及其应用
CN116284412A (zh) *	2021-12-21	2023-06-23	沈阳三生制药有限责任公司	一种抗masp-2抗体及其制备方法与用途
EP4493597A1 (en) *	2022-03-18	2025-01-22	Inmagene Pte. Ltd.	Masp-2-targetting antibodies and uses thereof
US20240228499A1 (en)	2022-11-30	2024-07-11	Omeros Corporation	Masp-2 inhibitors and methods of use
US12216123B2 (en)	2023-04-25	2025-02-04	Nuvance Health	Extracellular vesicle derived MASP-2 directed cancer treatment methods

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5211657A (en)	1988-11-07	1993-05-18	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5856121A (en)	1994-02-24	1999-01-05	Case Western Reserve University	Growth arrest homebox gene
JPH07238100A (ja)	1994-02-25	1995-09-12	Sumitomo Electric Ind Ltd	ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en)	1994-06-20	1998-04-21	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
AU4467396A (en)	1994-12-12	1996-07-10	Omeros Medical Systems, Inc.	Irrigation solution and method for inhibition of pain, inflammation and spasm
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
US6969601B2 (en)	1997-04-03	2005-11-29	Jensenius Jens Chr	MASP-2, a complement-fixing enzyme, and uses for it
WO2000035483A1 (en)	1998-12-15	2000-06-22	The Brigham And Women's Hospital, Inc.	Methods and products for regulating lectin complement pathway associated complement activation
KR20080099355A (ko)	1999-07-21	2008-11-12	오메로스 코포레이션	동통, 염증 및 연골 퇴화를 억제하기 위한 용액 및 억제방법
US20010051754A1 (en)	1999-08-03	2001-12-13	Daria N. Lissy	Plural stage toluene disproportionation process minimizing ethylbenzene
AU2001240020B9 (en) *	2000-03-01	2008-12-04	Medimmune, Llc	High potency recombinant antibodies and method for producing them
SG98393A1 (en)	2000-05-19	2003-09-19	Inst Materials Research & Eng	Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US7112414B2 (en) *	2000-07-13	2006-09-26	Jens Christian Jensenius	Masp-2, a complement-fixing enzyme, and uses for it
EP1300419B1 (en) *	2001-10-05	2007-06-13	Affimed Therapeutics AG	Antibody of human origin for inhibiting thrombocyte aggregation
US7435871B2 (en) *	2001-11-30	2008-10-14	Amgen Fremont Inc.	Transgenic animals bearing human Igλ light chain genes
CA2474645C (en)	2002-02-01	2011-08-09	Omeros Corporation	Compositions and methods for systemic inhibition of cartilage degradation
EP1531757B1 (en)	2002-07-19	2016-09-07	Omeros Corporation	Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US7396915B2 (en) *	2003-02-28	2008-07-08	Mitsubishi Pharma Corporation	Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent
US9096676B2 (en) *	2003-05-12	2015-08-04	Helion Biotech Aps	Antibodies to MASP-2
GB0412966D0 (en)	2004-06-10	2004-07-14	Univ Leicester	Genetically modified non-human mammals and cells
US8840893B2 (en)	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) *	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
WO2005123776A1 (en)	2004-06-10	2005-12-29	Omeros Corporation	Methods for treating conditions associated with lectin-dependent complement activation
DK1753456T3 (en) *	2004-06-10	2016-11-28	Omeros Corp	METHODS OF TREATING CONDITIONS CONNECTED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US8652477B2 (en)	2009-10-16	2014-02-18	Omeros Corporation	Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
JP5778577B2 (ja)	2008-09-19	2015-09-16	メディミューン，エルエルシー	Ｄｌｌ４に対する抗体およびその使用
WO2010054010A1 (en)	2008-11-07	2010-05-14	Fabrus Llc	Anti-dll4 antibodies and uses thereof
RS60541B1 (sr) *	2011-05-04	2020-08-31	Omeros Corp	Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa
PT2833907T (pt) *	2012-04-06	2018-05-29	Omeros Corp	Composições e métodos de inibição de masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de hemoglubinúria paroxística noturna

2012
- 2012-05-04 RS RS20200685A patent/RS60541B1/sr unknown
- 2012-05-04 EP EP12779347.9A patent/EP2704743B1/en active Active
- 2012-05-04 MX MX2013012862A patent/MX347691B/es active IP Right Grant
- 2012-05-04 EP EP19215429.2A patent/EP3725811A3/en active Pending
- 2012-05-04 SI SI201231793T patent/SI2704743T1/sl unknown
- 2012-05-04 CA CA3131223A patent/CA3131223C/en active Active
- 2012-05-04 JP JP2014509474A patent/JP5891298B2/ja active Active
- 2012-05-04 RU RU2013153527A patent/RU2636038C2/ru active
- 2012-05-04 CN CN201710201126.9A patent/CN107011443B/zh active Active
- 2012-05-04 KR KR1020137032078A patent/KR101641057B1/ko active Application Filing
- 2012-05-04 HU HUE12779347A patent/HUE049154T2/hu unknown
- 2012-05-04 CN CN201280032866.XA patent/CN103687620B/zh active Active
- 2012-05-04 ES ES12779347T patent/ES2795667T3/es active Active
- 2012-05-04 US US13/464,334 patent/US9011860B2/en active Active
- 2012-05-04 BR BR112013028429-3A patent/BR112013028429B1/pt active IP Right Grant
- 2012-05-04 KR KR1020167018831A patent/KR101882830B1/ko active IP Right Grant
- 2012-05-04 CA CA2832871A patent/CA2832871C/en active Active
- 2012-05-04 LT LTEP12779347.9T patent/LT2704743T/lt unknown
- 2012-05-04 WO PCT/US2012/036509 patent/WO2012151481A1/en active Application Filing
- 2012-05-04 SM SM20200294T patent/SMT202000294T1/it unknown
- 2012-05-04 PL PL12779347T patent/PL2704743T3/pl unknown
- 2012-05-04 PT PT127793479T patent/PT2704743T/pt unknown
- 2012-05-04 CA CA3025762A patent/CA3025762C/en active Active
- 2012-05-04 AU AU2012250627A patent/AU2012250627B2/en active Active
- 2012-05-04 ME MEP-2020-121A patent/ME03755B/me unknown
- 2012-05-04 MX MX2017006060A patent/MX361175B/es unknown
- 2012-05-04 DK DK12779347.9T patent/DK2704743T3/da active
- 2012-05-04 KR KR1020187021028A patent/KR102024016B1/ko active IP Right Grant
- 2012-11-03 IL IL229208A patent/IL229208B/en active IP Right Grant
2013
- 2013-10-30 CL CL2013003140A patent/CL2013003140A1/es unknown
- 2013-11-03 IL IL229208A patent/IL229208A0/en unknown
- 2013-11-04 MX MX2018014714A patent/MX2018014714A/es unknown
- 2013-11-27 ZA ZA2013/08943A patent/ZA201308943B/en unknown
2015
- 2015-03-17 US US14/660,040 patent/US9475885B2/en active Active
- 2015-09-09 JP JP2015177337A patent/JP6352226B2/ja active Active
2016
- 2016-09-13 US US15/263,876 patent/US10047165B2/en active Active
2017
- 2017-10-31 RU RU2017137872A patent/RU2725958C2/ru active
2018
- 2018-04-04 JP JP2018072245A patent/JP6669800B2/ja active Active
- 2018-07-13 US US16/034,896 patent/US10683367B2/en active Active
2019
- 2019-05-20 IL IL266756A patent/IL266756B/en unknown
2020
- 2020-02-27 JP JP2020031661A patent/JP2020097630A/ja not_active Withdrawn
- 2020-04-24 US US16/857,558 patent/US11613589B2/en active Active
- 2020-06-02 HR HRP20200887TT patent/HRP20200887T1/hr unknown
- 2020-06-10 CY CY20201100525T patent/CY1123212T1/el unknown
- 2020-06-22 RU RU2020120539A patent/RU2020120539A/ru unknown
2021
- 2021-08-10 IL IL285522A patent/IL285522A/en unknown
2022
- 2022-09-02 JP JP2022139872A patent/JP2022172275A/ja not_active Withdrawn
2023
- 2023-02-13 US US18/168,192 patent/US20240092938A1/en active Pending
2024
- 2024-09-10 JP JP2024156933A patent/JP2024170616A/ja active Pending

Also Published As

Publication number	Publication date
CA2832871A1 (en)	2012-11-08
MX361175B (es)	2018-11-29
LT2704743T (lt)	2020-09-10
ME03755B (me)	2021-04-20
EP2704743A1 (en)	2014-03-12
KR20160087917A (ko)	2016-07-22
BR112013028429B1 (pt)	2022-11-08
CA3131223A1 (en)	2012-11-08
JP2014515922A (ja)	2014-07-07
CN103687620A (zh)	2014-03-26
CN107011443A (zh)	2017-08-04
US9011860B2 (en)	2015-04-21
EP2704743B1 (en)	2020-03-11
IL229208A0 (en)	2014-01-30
NZ733310A (en)	2021-12-24
EP3725811A3 (en)	2021-01-27
JP6669800B2 (ja)	2020-03-18
EP3725811A2 (en)	2020-10-21
US10047165B2 (en)	2018-08-14
US9475885B2 (en)	2016-10-25
JP2024170616A (ja)	2024-12-10
IL266756A (en)	2019-07-31
IL266756B (en)	2021-08-31
KR20140006096A (ko)	2014-01-15
RU2725958C2 (ru)	2020-07-07
RU2636038C2 (ru)	2017-11-17
RU2013153527A (ru)	2015-06-10
NZ617487A (en)	2016-03-31
RU2020120539A (ru)	2021-12-23
SI2704743T1 (sl)	2020-08-31
JP2015227380A (ja)	2015-12-17
CA2832871C (en)	2019-01-15
KR101882830B1 (ko)	2018-07-31
KR20180086298A (ko)	2018-07-30
AU2012250627A1 (en)	2013-03-21
PT2704743T (pt)	2020-06-17
US20240092938A1 (en)	2024-03-21
IL285522A (en)	2021-09-30
RU2017137872A (ru)	2019-04-30
CY1123212T1 (el)	2021-10-29
US20210054099A1 (en)	2021-02-25
PL2704743T3 (pl)	2020-08-24
JP2020097630A (ja)	2020-06-25
DK2704743T3 (en)	2020-05-25
JP5891298B2 (ja)	2016-03-22
WO2012151481A1 (en)	2012-11-08
CA3131223C (en)	2024-01-30
CA3025762A1 (en)	2012-11-08
US20190119402A1 (en)	2019-04-25
CA3025762C (en)	2021-11-09
SMT202000294T1 (it)	2020-07-08
KR102024016B1 (ko)	2019-11-04
BR112013028429A2 (pt)	2020-07-21
AU2012250627B2 (en)	2016-01-07
US10683367B2 (en)	2020-06-16
ES2795667T3 (es)	2020-11-24
MX347691B (es)	2017-05-09
HUE049154T2 (hu)	2020-09-28
US11613589B2 (en)	2023-03-28
MX2013012862A (es)	2013-12-02
US20120282263A1 (en)	2012-11-08
IL229208B (en)	2021-03-25
CL2013003140A1 (es)	2014-05-23
HRP20200887T1 (hr)	2020-09-04
JP6352226B2 (ja)	2018-07-04
NZ715226A (en)	2017-07-28
RU2017137872A3 (sr)	2019-04-30
US20170088632A1 (en)	2017-03-30
ZA201308943B (en)	2015-05-27
JP2022172275A (ja)	2022-11-15
CN107011443B (zh)	2021-04-30
CN103687620B (zh)	2017-10-13
KR101641057B1 (ko)	2016-07-20
EP2704743A4 (en)	2014-11-05
JP2018123148A (ja)	2018-08-09
US20160002349A1 (en)	2016-01-07
MX2018014714A (es)	2021-11-16

Publication	Publication Date	Title
DK2704743T3 (en)	2020-05-25	Compositions for inhibiting masp-2 dependent complement acitivation
HK1203403A1 (en)	2015-10-30	Peracid-generating compositions
HK1192578A1 (zh)	2014-08-22	抗結皮組合物
SG11201401335QA (en)	2014-05-29	Compositions
GB201117619D0 (en)	2011-11-23	Compositions
GB201117621D0 (en)	2011-11-23	Compositions
GB2496447B (en)	2015-04-22	Compositions
GB201110833D0 (en)	2011-08-10	Compositions
GB201103942D0 (en)	2011-04-20	Compositions
HK1201687A1 (en)	2015-09-11	Improved compositions
PL2717690T3 (pl)	2020-11-02	Kompozycje okulistyczne
GB201110132D0 (en)	2011-07-27	compositions
GB201104849D0 (en)	2011-05-04	Compositions
GB201122216D0 (en)	2012-02-01	Compositions
GB201122214D0 (en)	2012-02-01	Compositions
GB201122213D0 (en)	2012-02-01	Compositions
GB201121028D0 (en)	2012-01-18	Compositions
GB201120406D0 (en)	2012-01-11	Compositions
GB201117234D0 (en)	2011-11-16	Compositions
GB201117165D0 (en)	2011-11-16	Compositions
GB201114629D0 (en)	2011-10-05	Compositions
GB201109121D0 (en)	2011-07-13	Compositions
GB201108338D0 (en)	2011-06-29	Compositions
GB201107998D0 (en)	2011-06-29	Compositions
GB201108040D0 (en)	2011-06-29	Compositions